A Phase 3 Randomized, Open-Label, Multinational, Multicenter Study of the Efficacy and Safety of MEDI-522 (AbegrinTM), a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, compared to Dacarbazine (DTIC) for the Treatment of Patients with Unresectable Stage IIIC or Stage IV Metastatic Melanoma

Trial Profile

A Phase 3 Randomized, Open-Label, Multinational, Multicenter Study of the Efficacy and Safety of MEDI-522 (AbegrinTM), a Humanized Monoclonal Antibody Directed Against the Human Alpha V Beta 3 Integrin, compared to Dacarbazine (DTIC) for the Treatment of Patients with Unresectable Stage IIIC or Stage IV Metastatic Melanoma

Suspended
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2013

At a glance

  • Drugs Etaracizumab (Primary) ; Dacarbazine
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top